About the Study

High-grade Glioma (HGG) with BRAFV600-mutation: A clinical trial of dabrafenib and trametinib after radiation therapy

This study is for: • People who are ages 3 through 21 • Who are newly diagnosed with high-grade glioma (HGG) with BRAFV600-mutation High-grade gliomas (HGGs) are hard to treat successfully. Two drugs that will be used in this study are dabrafenib and trametinib. This study will look at how well the combination of dabrafenib and trametinib works when given to children and young adults with HGGs after they receive radiation therapy. The use of this combination to treat pediatric brain tumors is experimental.

Interested in learning more?

Full Study Name: ACNS1723 - A Phase 2 Study of Dabrafenib with Trametinib after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG)